Drugs / JH021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07582822 | May 2026 → May 2028 expected | neoplastic disease or syndrome | Biotech Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JH021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07582822 ↗ |
| Modality | Monoclonal antibody | “bispecific monoclonal antibody” NCT07582822 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07582822 ↗ |
| Target | EGFR | “targeting EGFR and cMET” NCT07582822 ↗ |
| Target | MET | “targeting EGFR and cMET” NCT07582822 ↗ |